Summary & Overview
HCPCS C9040: Injection of fremanezumab-vfrm, 1 mg
HCPCS Level II code C9040 denotes a 1 mg unit of fremanezumab-vfrm, a monoclonal antibody injection used in clinical settings that administer preventive biologic therapy. This code matters nationally as it standardizes reporting and billing for a high-cost injectable biologic across outpatient clinics, physician offices, and infusion centers, affecting coverage, utilization monitoring, and payer policy alignment.
Key payers covered in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what C9040 represents clinically and operationally, benchmark considerations for unit-based billing, implications for site-of-service reporting, and common administrative topics that influence reimbursement and coverage decisions. The summary highlights policy-relevant points such as unitization per milligram, the typical outpatient administration setting, and areas where payer-specific prior authorization and medical necessity rules commonly apply.
This national-level brief is intended to orient clinicians, billing staff, and policy analysts to the code’s purpose, where it is used, and the types of payer interactions to expect. Specific payer policies, modifiers, taxonomies, ICD-10 associations, and related codes are not included here; Data not available in the input.
Billing Code Overview
HCPCS Level II code C9040 represents an injection of fremanezumab-vfrm, billed per 1 mg. The service type is medication administration (monoclonal antibody injection). The typical site of service is outpatient clinic or physician office infusion/administration area, including specialty infusion centers and ambulatory treatment settings.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with chronic migraine who presents to a neurology or headache clinic for preventive therapy. The patient has a documented history of migraine headaches occurring on 8 or more days per month despite trials of at least two oral preventive medications (for example, a beta-blocker, tricyclic antidepressant, or anticonvulsant) or has intolerance/contraindication to those agents. The clinician evaluates headache frequency, severity, prior preventive treatment history, and comorbidities, obtains informed consent, and documents indication for monoclonal antibody therapy targeting calcitonin gene‑related peptide (CGRP).
The service consists of administration of the monoclonal antibody fremanezumab‑vfrm via subcutaneous injection. The medication is billed per milligram using the HCPCS Level II code C9040 (Injection, fremanezumab‑vfrm, 1 mg). Typical workflow steps include verification of identity and insurance benefits, medication preparation and dosage calculation, patient education about expected onset and possible adverse reactions, site selection and aseptic technique for subcutaneous injection, observation for immediate reactions (typically 15–30 minutes), and documentation of lot number, dose administered, and route. Follow‑up appointments are scheduled to assess effectiveness and tolerability, and subsequent administrations are scheduled per the prescribing regimen (monthly or quarterly dosing as indicated).
Typical site of service is an outpatient infusion or injection clinic, neurology clinic, or office-based procedure room with appropriate emergency preparedness. Patients may also receive the injection in an ambulatory care center or specialty pharmacy clinic when onsite administration is provided.
Coding Specifications
| Modifier | Description |
|---|